LRFN2 Inhibitors
Chemical inhibitors of LRFN2 function by interacting with various signaling pathways and kinases that are crucial for the protein's role in synaptic signaling and plasticity. Src family kinase inhibitors, such as PD173955, PP2, Dasatinib, and SU6656, directly target the Src family tyrosine kinases which are known to phosphorylate substrates involved in modulating synapse formation and maintenance. These inhibitors prevent the activation of Src kinases, thus potentially reducing the phosphorylation of proteins within signaling pathways where LRFN2 is involved. For example, PD173955 can lead to a decrease in the functional interactions of LRFN2 with its synaptic partners, while Dasatinib's broad-spectrum inhibition may affect cell adhesion and synaptic plasticity, processes where LRFN2 plays a role. SU6656, being more selective, specifically impacts the signaling related to LRFN2's function in synaptic regulation.
On the other hand, inhibitors like Lapatinib and Gefitinib target the ErbB and EGFR signaling pathways, respectively, which can influence processes such as neurite outgrowth and synaptic plasticity, where LRFN2 has been implicated. By inhibiting these pathways, Lapatinib and Gefitinib can reduce the activities associated with LRFN2 in these domains. MEK inhibitor U0126 and JNK inhibitor SP600125 interfere with the MAPK/ERK and JNK pathways, respectively, which are pathways LRFN2 may utilize. U0126 can inhibit LRFN2-mediated signaling events tied to the MAPK/ERK pathway, while SP600125 would inhibit LRFN2's role in processes that JNK influences. SB203580, a p38 MAP kinase inhibitor, would affect LRFN2-related functions by inhibiting p38 MAPK signaling involved in synaptic changes. PI3K/Akt pathway inhibitors LY294002 and Wortmannin would impede the pathway crucial for synapse formation and maintenance, thereby inhibiting LRFN2's function in these synaptic processes. Lastly, Rapamycin, an mTOR inhibitor, would impede mTOR signaling, which is important for synaptic plasticity and neuron growth, areas where LRFN2's influence is noted. Each of these inhibitors targets specific molecular interactions and signaling cascades that are key to LRFN2's role in the neuron.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 173955 | 260415-63-2 | sc-507378 | 10 mg | $320.00 | ||
PD173955 is a Src family kinase inhibitor that can inhibit the phosphorylation of proteins within signaling pathways. Since LRFN2 interacts with synaptic proteins and Src kinase activity can regulate synaptic protein interactions, inhibition of Src by PD173955 can lead to reduced functional interactions of LRFN2 with its partners at synapses. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is another Src family tyrosine kinase inhibitor. It would inhibit LRFN2 function by blocking Src family kinases that phosphorylate substrates involved in the modulation of synapse formation and maintenance, where LRFN2 is known to play a role. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is an EGFR and ErbB2 inhibitor that can inhibit the ErbB signaling pathway. LRFN2 has been implicated in neurite outgrowth, a process that can be influenced by ErbB signaling. By inhibiting this pathway, Lapatinib can reduce the neurite outgrowth activities associated with LRFN2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that affects the Src family kinases, Abl, and c-Kit which are involved in cell adhesion and synaptic plasticity. Since LRFN2 is implicated in cell adhesion processes at synapses, Dasatinib can inhibit these functions of LRFN2. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $56.00 $130.00 | 27 | |
SU6656 is a selective Src family kinase inhibitor. By inhibiting Src kinases, it can impact the signaling related to synaptic function and plasticity. Since LRFN2 is involved in synaptic regulation, SU6656 would inhibit its functional role within these processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor which would inhibit the MAPK/ERK pathway. LRFN2, through its interactions in synaptic signaling, can be tied to MAPK/ERK pathway activities, and thus U0126 can inhibit these LRFN2-mediated signaling events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which would inhibit the JNK signaling pathway. As LRFN2 is known to be involved in neurite outgrowth and synaptic plasticity, processes that JNK can influence, SP600125 would inhibit LRFN2's role in these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Since p38 MAPK signaling is involved in inflammatory responses and synaptic changes, and LRFN2 has a role in synapse formation and maintenance, SB203580 would inhibit these LRFN2-related functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which would inhibit the PI3K/Akt pathway. LRFN2, involved in synapse formation and maintenance, would have its function inhibited by LY294002 through the attenuation of the PI3K/Akt pathway which is crucial for these synaptic processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that would inhibit the PI3K/Akt signaling pathway. By disrupting this pathway, Wortmannin would inhibit synaptic functions where LRFN2 is engaged, as PI3K/Akt is key in synaptic signaling and plasticity. | ||||||